Inclusion Complex of Novel Curcumin Analogue CDF and β-Cyclodextrin (1:2) and Its EnhancedIn VivoAnticancer Activity Against Pancreatic Cancer
✍ Scribed by Prasad R. Dandawate, Alok Vyas, Aamir Ahmad, Sanjeev Banerjee, Jyoti Deshpande, K. Venkateswara Swamy, Abeda Jamadar, Anne Catherine Dumhe-Klaire, Subhash Padhye, Fazlul H. Sarkar
- Book ID
- 113077681
- Publisher
- Springer US
- Year
- 2012
- Tongue
- English
- Weight
- 676 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0724-8741
No coin nor oath required. For personal study only.
✦ Synopsis
Purpose Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-β-cyclodextrin inclusion complex (1:2) (CDFCD). Methods The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked. Results CDF-β-cyclodextrin was found to lower IC 50 value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-β-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-β-cyclodextrin preparation. Conclusions Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-βcyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.